Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05220098




Registration number
NCT05220098
Ethics application status
Date submitted
7/01/2022
Date registered
2/02/2022
Date last updated
5/09/2024

Titles & IDs
Public title
First-in-Human Study of TAK-280 in Participants With Solid Tumors
Scientific title
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer
Secondary ID [1] 0 0
2023-504012-16
Secondary ID [2] 0 0
TAK-280-1501
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Unresectable Locally Advanced or Metastatic Cancer 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - TAK-280

Experimental: Dose-escalation Phase: TAK-280 - Participants will receive TAK-280 intravenous (IV) infusion on Days 1, 8, 15, and 22 of a 28-day treatment cycle until disease progression, unacceptable toxicity, or withdrawal from study occurs.

Experimental: Cohort-expansion Phase: TAK-280 High or low Dose - Participants will receive either TAK-280 high or low dose in one selected indication and only one dose level of TAK-280 in the remaining indications as determined from the dose-escalation phase of the study in 28-day treatment cycle until disease progression, unacceptable toxicity, or withdrawal from study occurs.


Treatment: Drugs: TAK-280
Participants will receive TAK-280 as IV infusion.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants With Dose Limiting Toxicities (DLTs)
Timepoint [1] 0 0
From start of the initial dose up to Cycle 1 Day 28
Primary outcome [2] 0 0
Number of Participants With Treatment- emergent Adverse Events (TEAEs)
Timepoint [2] 0 0
Up to approximately 37 months
Secondary outcome [1] 0 0
Maximum Observed Plasma Concentration (Cmax) of TAK-280
Timepoint [1] 0 0
Pre-dose and at multiple time points post-dose on Days 1, 2, 3, 8, 15, 22 up to the end of treatment (Up to 14 months)
Secondary outcome [2] 0 0
Area Under Plasma Concentration-Time Curve (AUC) of TAK- 280
Timepoint [2] 0 0
Pre-dose and at multiple time points post-dose on Days 1, 2, 3, 8, 15, 22 up to the end of treatment (Up to 14 months)
Secondary outcome [3] 0 0
Time to Reach Maximum Observed Plasma Concentration (tmax) of TAK-280
Timepoint [3] 0 0
Pre-dose and at multiple time points post-dose on Days 1, 2, 3, 8, 15, 22 up to the end of treatment (Up to 14 months)
Secondary outcome [4] 0 0
Terminal Disposition Phase Half-Life (t1/2) of TAK-280
Timepoint [4] 0 0
Pre-dose and at multiple time points post-dose on Days 1, 2, 3, 8, 15, 22 up to the end of treatment (Up to 14 months)
Secondary outcome [5] 0 0
Total Clearance (CL) of TAK-280
Timepoint [5] 0 0
Pre-dose and at multiple time points post-dose on Days 1, 2, 3, 8, 15, 22 up to the end of treatment (Up to 14 months)
Secondary outcome [6] 0 0
Volume of Distribution at Steady State (Vss) After IV Administration of TAK-280
Timepoint [6] 0 0
Pre-dose and at multiple time points post-dose on Days 1, 2, 3, 8, 15, 22 up to the end of treatment (Up to 14 months)
Secondary outcome [7] 0 0
Confirmed Overall Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST V1.1)
Timepoint [7] 0 0
Up to approximately 37 months
Secondary outcome [8] 0 0
Duration of Response (DOR) Based on RECIST V1.1
Timepoint [8] 0 0
Up to approximately 37 months
Secondary outcome [9] 0 0
Progression Free Survival (PFS)
Timepoint [9] 0 0
From start of first dose to disease progression or death, whichever occurred first (up to approximately 37 months)
Secondary outcome [10] 0 0
Overall Survival (OS)
Timepoint [10] 0 0
From start of first dose of study drug up to death (up to approximately 37 months)
Secondary outcome [11] 0 0
Disease Control Rate
Timepoint [11] 0 0
Up to approximately 37 months
Secondary outcome [12] 0 0
Percentage of Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Having Prostate-Specific Antigen (PSA) Response
Timepoint [12] 0 0
Up to approximately 37 months
Secondary outcome [13] 0 0
Duration of PSA Response in Participants With mCRPC
Timepoint [13] 0 0
Up to approximately 37 months
Secondary outcome [14] 0 0
Time to PSA Progression in Participants With mCRPC
Timepoint [14] 0 0
Up to approximately 37 months
Secondary outcome [15] 0 0
Percentage of Participants With mCRPC Having PSA Reductions of >= 50% up to 6 Months
Timepoint [15] 0 0
Baseline up to 6 months
Secondary outcome [16] 0 0
Percentage of Participants who Develop Positive Induced Antidrug Antibody (ADA) for TAK-280
Timepoint [16] 0 0
Cycle 1 to 5: pre-dose (Each cycle= 28 days)
Secondary outcome [17] 0 0
Percentage of Participants who Developed Neutralizing Antibody (NAb) Titers for TAK-280
Timepoint [17] 0 0
Cycle 1 to 5: pre-dose (Each cycle= 28 days)

Eligibility
Key inclusion criteria
Inclusion Criteria

* Age greater than or equal to (>=)18 years or >= the local legal age of majority, as applicable.
* Criteria for disease state in dose escalation and cohort expansion.

1. Tumor histologies during dose escalation: Dose escalation will begin by initially enrolling participants with histologically or pathologically confirmed, unresectable, locally advanced or metastatic cancers.
2. Tumor histologies during cohort expansion: Participants will be eligible if they have histologically proven, unresectable, locally advanced or metastatic malignant neoplasms.
* Eastern Cooperative Oncology Group performance status (less than or equal to [<=]) 1.
* Measurable disease per RECIST V1.1 by investigator except for participants with mCRPC with bone metastases only (these participants are allowed in the study). Lesions in previously irradiated areas (or other local therapy) should not be selected as measurable/target lesions, unless treatment was >=6 months prior to start of treatment or there has been demonstrated progression with a clear margin to measure in that particular lesion.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion Criteria

* History of known autoimmune disease.
* Major surgery or traumatic injury within 8 weeks before the first dose of TAK-280.
* Unhealed wounds from surgery or injury.
* Ongoing or active infection of Grade >=2.
* Oxygen saturation less than (<) 92 percent (%) on room air at screening or during Cycle 1 Day 1 (C1D1) predose assessment.
* Inflammatory process that has not resolved for >= 4 weeks before the first dose of study drug. Participants with chronic low-grade inflammatory processes such as radiation-induced pneumonitis are excluded regardless of their duration.
* Vaccination with any live virus vaccine within 4 weeks or other vaccines within 2 weeks before the initiation of study drug administration. Inactivated annual influenza vaccination is allowed.
* Known hypersensitivity to TAK-280 or any excipient.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
22/04/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/07/2026
Actual
Sample size
Target
182
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Chris O'Brien Lifehouse Hospital - Camperdown
Recruitment hospital [2] 0 0
Southern Oncology Clinical Research Unit - Bedford Park
Recruitment hospital [3] 0 0
Monash Medical Centre - Clayton
Recruitment hospital [4] 0 0
Cabrini Health - Malvern
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
5042 - Bedford Park
Recruitment postcode(s) [3] 0 0
3168 - Clayton
Recruitment postcode(s) [4] 0 0
3144 - Malvern
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arkansas
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Minnesota
Country [4] 0 0
United States of America
State/province [4] 0 0
Ohio
Country [5] 0 0
United States of America
State/province [5] 0 0
South Dakota
Country [6] 0 0
United States of America
State/province [6] 0 0
Tennessee
Country [7] 0 0
United States of America
State/province [7] 0 0
Texas
Country [8] 0 0
United States of America
State/province [8] 0 0
Wisconsin
Country [9] 0 0
Canada
State/province [9] 0 0
Quebec
Country [10] 0 0
Canada
State/province [10] 0 0
Sherbrooke
Country [11] 0 0
Canada
State/province [11] 0 0
Toronto
Country [12] 0 0
Spain
State/province [12] 0 0
Barcelona
Country [13] 0 0
Spain
State/province [13] 0 0
Madrid
Country [14] 0 0
Spain
State/province [14] 0 0
Malaga
Country [15] 0 0
Spain
State/province [15] 0 0
Valencia

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Takeda
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Takeda Development Center Americas, Inc.
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The main aim of this study is to find out the safety, tolerability, and effect of TAK- 280 in participants with unresectable, locally advanced or metastatic cancer who have experienced treatment failure or are intolerant to standard therapies.

Participants will be treated with TAK-280 for up to 14 treatment cycles. Each treatment cycle will be 28 days.

After the last dose of study drug, participants will be followed up for survival every 12 weeks for a total of 48 weeks.
Trial website
https://clinicaltrials.gov/study/NCT05220098
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Study Director
Address 0 0
Takeda
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Takeda Contact
Address 0 0
Country 0 0
Phone 0 0
+1-877-825-3327
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05220098